Mutations in CHD7, encoding ATP-dependent chromodomain helicase DNA-binding protein 7, in CHARGE syndrome lead to multiple congenital anomalies, including craniofacial malformations, neurological dysfunction and growth delay. Mechanisms underlying the CNS phenotypes remain poorly understood. We found that Chd7 is a direct transcriptional target of oligodendrogenesis-promoting factors Olig2 and Smarca4/Brg1 and is required for proper onset of CNS myelination and remyelination. Genome-occupancy analyses in mice, coupled with transcriptome profiling, revealed that Chd7 interacted with Sox10 and targeted the enhancers of key myelinogenic genes. These analyses identified previously unknown Chd7 targets, including bone formation regulators Osterix (also known as Sp7) and Creb3l2, which are also critical for oligodendrocyte maturation. Thus, Chd7 coordinates with Sox10 to regulate the initiation of myelinogenesis and acts as a molecular nexus of regulatory networks that account for the development of a seemingly diverse array of lineages, including oligodendrocytes and osteoblasts, pointing to previously uncharacterized Chd7 functions in white matter pathogenesis in CHARGE syndrome. npg
a r t I C l e S Chromatin remodeling control is essential for orchestrating cell growth and differentiation and to maintain proper cell identity 1, 2 . Mutations in chromatin-modifying enzymes have been implicated in the pathogenesis of various human diseases, manifesting in growth and developmental defects, neurological disorders, and tumorigenesis 3, 4 . One class of chromatin-modifying enzymes, the chromodomain helicase DNA-binding (CHD) family of SNF2H-like ATP-dependent nucleosome remodeling enzymes, has emerged as an important regulator of multiple biological processes 5 . Mutations in CHD7 are the major cause of human CHARGE syndrome (coloboma of the eye, heart defects, atresia of the choanae, severe retardation of growth/development, genital abnormalities and ear abnormalities), an autosomal dominant disorder that is characterized by a nonrandom association of multiple birth defects that impair normal development 5, 6 . The life expectancy of CHARGE patients ranges from 5 d to ~46 years 7 . CHD7 modulates chromatin configurations to control cell type-specific transcriptional machinery, thereby controlling temporal and spatial gene expression [8] [9] [10] [11] . Most CHARGE patients exhibit some degree of intellectual disability, and many present with structural abnormalities of the corpus callosum and cerebellar vermis 5, 12 . Recent reports of white matter defects in the brains of patients with CHARGE syndrome 13, 14 suggest a possible role for CHD7 in myelination in the CNS.
Oligodendrocytes (OLs) produce myelin sheaths that electrically insulate axons and promote rapid propagation of action potentials in the CNS. Failure of OLs to remyelinate demyelinated axons disrupts saltatory nerve conduction, which could lead to cognitive and motor function deficits or irreversible axonal degeneration in disorders such as multiple sclerosis (MS) and leukodystrophies [15] [16] [17] . The onset and timing of CNS myelination and remyelination is tightly regulated by the balanced intrinsic and extrinsic cues [18] [19] [20] . Differentiation of OL precursor cells (OPCs) into mature OLs requires precise coordination between epigenetic programming and transcriptional regulation. Chromatin reorganization is critical for OL differentiation processes 21 . Recently, the SWI/SNF chromatin-remodeling enzyme Smarca4 (Brg1) has been demonstrated to complex with a pioneer transcription factor Olig2 to target active enhancer elements to initiate the differentiation of OL lineage cells 22 .
We identified Chd7 as a downstream target of Brg1 and Olig2. We found that expression of Chd7 was highly enriched in OL lineage cells, with a peak of expression in differentiating OLs. Inactivation of Chd7 caused defects in OL differentiation and myelination while sparing OPC formation. In addition, we found that Chd7 was required for OL remyelination after demyelinating injury. Genome-wide mapping of Chd7 targeting sites and co-immunoprecipitation revealed that Chd7 complexed with Sox10 and directly activated a distinct set of critical a r t I C l e S regulators for OL differentiation. Moreover, our results identify the osteoblast-differentiation factor Osterix as an OL-specific Chd7 downstream target in the CNS and demonstrate a critical requirement of Osterix for OL differentiation. Collectively, these data provide evidence that the chromatin remodeler Chd7 interacts with Sox10 to bridge Brg1 and Olig2 activity during OL differentiation and controls the onset of OL myelination and remyelination by directly activating myelinogenic programs.
RESULTS
OL-enriched Chd7 is a direct target of Brg1 and Olig2 complex We have shown that Brg1 and Olig2 co-occupancy in the genome establishes a transcriptional program to initiate OPC differentiation 22 . We integrated transcriptome profiling of the spinal cord from Brg1 conditional knockout (Brg1cKO) mutant mice (Brg1 loxP/loxP ; Olig1-Cre +/− ) by gene-chip microarray 22 and genome-wide Brg1 and Olig2 occupancy at multiple phases of OL differentiation, and identified Chd7 as a candidate target gene of Brg1 and Olig2. Brg1 and Olig2 bound strongly at multiple sites both around the promoter region and in the Chd7 gene locus, accompanied by the presence of an activated histone acetylation mark H3K27Ac in OPCs and early differentiating immature OLs (iOLs) (Fig. 1a) . Expression of Chd7 was substantially downregulated in Brg1cKO mice (Fig. 1b) . Consistently, the number Chd7-expressing cells appeared to be markedly reduced in the Brg1cKO spinal cord at postnatal day 14 (P14) (Fig. 1c) . These observations suggest that Chd7 is a downstream target of Brg1 and Olig2.
To further characterize Chd7-expressing cell types in the developing cortex, we co-immunostained Chd7 with cell type-specific markers, including Olig2 for the OL lineage, CC1 for OLs, glial fibrillary acidic protein (GFAP) and glutamine synthetase (GS) for astrocytes, and a pan-neuronal marker NeuN. Chd7 was detected in most Olig2-positive cells (Fig. 1d) . The majority of Chd7 + cells in the OL lineage were CC1 + differentiated OLs in the corpus callosum, optic nerve and spinal cord at P14 ( Fig. 1e-h) . Intense Chd7 expression was detected in OLs, but at a lower level in PDGFRα + OPCs (Fig. 1i) in the P14 cortex. Similarly, in culture, Chd7 appeared to be more robustly expressed in MBP + (myelin basic protein) mature OLs than in PDGFRα + OPCs (Fig. 1m ), suggesting a potential role of Chd7 at the OL differentiation onset. In contrast, we did not observe Chd7 expression in GFAP + or GS + astrocytes in the corpus callosum ( Fig. 1j,k) . In addition, Chd7 was hardly detectable in NeuN + neurons in the cortex at P24 (Fig. 1l) . These data reveal that Chd7 is highly enriched in differentiating OLs in the developing CNS.
To explore the potential function of Chd7 in human CNS myelination, we examined the white matter of a cohort of 17 patients with CHARGE syndrome carrying CHD7 mutations. Magnetic resonance imaging (MRI) scans revealed severe cerebral white matter defects in 47% (8 of 17) of the CHARGE patients. Compared with the agematched normal brain, the brains of these patients exhibited volumetric loss of cerebral white matter ( Fig. 1n ) and dysmorphic features in the white matter regions of the brainstem and cerebellum ( Fig. 1o ) that are commonly seen in patients with CHARGE syndrome 13 , indicating that white matter defects are a prominent feature of CHARGE syndrome with CHD7 mutations. These observations, together with Chd7 expression in the OL lineage, raise the possibility that CHD7 may be functionally required for CNS myelination in humans.
Chd7 is required for proper myelination in the CNS
To investigate the function of Chd7 in CNS myelination in vivo, we selectively ablated Chd7 in OL lineage cells by breeding the floxed Chd7 allele with mice carrying an OL-lineage expressing Olig1-Cre line ( Fig. 2a) . Chd7 expression was substantially reduced in the corpus callosum of the Chd7 conditional knockout mice (Chd7 loxP/loxP ; Olig1-Cre +/− , Chd7cKO) at P14, suggesting that the floxed Chd7 allele was effectively recombined in the Chd7cKO brain as compared with the control (Chd7 loxP/+ ;Olig1-Cre +/− ) ( Fig. 2b) . Chd7cKO animals were born at the expected Mendelian frequency and were of normal body size and weight. The analysis of appearance of MBP at embryonic stages and early postnatal stages indicated a substantial reduction of MBP-expressing OLs in the spinal cord of Chd7cKO animals (Supplementary Fig. 1a-c) . Similarly, expression of Mbp and Plp1 (proteolipid protein 1) mRNAs was visibly diminished in both the spinal cord and corpus callosum of Chd7cKO mice at neonatal and perinatal stages ( Fig. 2c,d) . In addition, the numbers of CC1 + OLs and OL lineage cells marked by Olig1, Olig2, and Sox10 in Chd7cKO cortices were significantly decreased ( Fig. 2e,f and Supplementary  Fig. 2a-d) . Consistently, MBP-expressing area assayed by immunohistochemistry was much less in the corpus callosum of Chd7cKO mice ( Fig. 2g) . Cerebral white matter volume assessed by total MBP + area in the corpus callosum was significantly reduced in developing Chd7cKO mice (Fig. 2g,h and Supplementary Fig. 2e ). These observations suggest that Chd7 is required for the onset of OL differentiation in the CNS.
Consistent with the reduction in mature OLs, ultrastructural analysis of optic nerves revealed compromised axonal ensheathment, with a markedly reduced number of myelinated axons in Chd7cKO animals at P14 (Fig. 2i,k) . At P28, the number of myelinating axons increased, but was still less than the control (Fig. 2j,k) . Notably, the thickness of myelin sheaths measured by g-ratio (the ratio between the diameter of the axon itself and the axon plus its myelin sheath), was substantially thinnein Chd7cKO optic nerves than in controls ( Fig. 2j,l) . Notably, this hypomyelination effect appeared to be transient, as the number of CC1 + OLs gradually increased during development and finally caught up in the spinal cord of adult mice ( Supplementary Fig. 3a,b) . By P60, the degree of myelination was essentially indistinguishable in the spinal cord between control and Chd7cKO mice ( Supplementary  Fig. 3c,d) . Thus, these observations indicate that Chd7 loss causes a markedly delay in CNS myelination and that increased numbers of differentiated OLs may account for the myelination recovery in adult Chd7cKO animals.
Chd7 regulates the transition from OPC to OL Given the possibility that the dysmyelinating phenotype in Chd7cKO mice could be a result of a failure to generate OPCs, we assessed OPC development in the brain. Expression of the OPC marker PDGFRα was comparable between control and Chd7cKO cortices at P7 and P14 ( Fig. 3a) . Quantification of PDGFRα + cells at postnatal stages (P0, P7 and P21) indicated that deletion of Chd7 did not alter OPC formation (Fig. 3b) . Supporting this, we found similar OPC proliferation rates (percentage of Ki67 + proliferative OPCs; Fig. 3c,d ) and survival (absence of activated Caspase 3; Supplementary Fig. 4 ) between Chd7cKO and control mice. It is also noteworthy that Chd7 inactivation in the OL lineage did not lead to notable alterations in astrocytes and neurons expressing GFAP and NeuN, respectively ( Supplementary Fig. 4) .
To further determine whether defects in OL differentiation are a cell-autonomous effect of Chd7 ablation, we purified OPCs from the neonatal cortex of Chd7 loxP/loxP pups, transduced them with adenoviral vectors expressing either eGFP as a control (Ade-GFP) or Cre-IRES-eGFP (Ade-Cre-GFP), and analyzed their ability to differentiate in vitro after withdrawal of the mitogens PDGFAA and NT3. Chd7 loxP/loxP OPCs transduced with Ade-GFP or wild-type npg a r t I C l e S OPCs transduced with Ade-Cre-GFP were able to differentiate into mature MBP + OLs. Chd7 loxP/loxP cells transduced with Ade-Cre-GFP, however, essentially failed to differentiate into MBP + OLs (Fig. 3e,f) , suggesting that Chd7-deleted OPCs are intrinsically defective in maturation.
To examine the effects of inactivation of Chd7 on OPC differentiation during postnatal development in a time-controlled manner, we generated OPC-inducible Chd7 mutants by breeding Chd7 loxP/loxP mice with PDGFRα-CreER T mice, which express OPC-specific tamoxifen-inducible Cre 23 and a Rosa26 tdTomato reporter. Tamoxifen administration in PDGFRα-CreER T :Chd7 loxP/loxP mutants (Chd7-iKO) pups at P3 induced effective recombination of both Chd7 and Rosa26 loci, with approximately 90% of PDGFRα + OPCs expressing tdTomato and not Chd7 after 11 d post-induction ( Fig. 3g ). Loss of Chd7 in OPCs led to a marked (~76%) reduction in differentiating OLs (CC1 high -expressing cells) in the cortical regions of Chd7-iKO mice compared with control littermates (PDGFRα-CreER T :Chd7 loxP/+ ) ( Fig. 3h,j) . Similarly, expression of myelin oligodendrocyte glycoprotein (MOG) in mature OLs was reduced compared with robust expression in controls ( Fig. 3i,j) Chd7 is critical for OL remyelination after demyelination Given that myelination was normal in adult Chd7cKO animals, that is, the numbers of myelinated axons and myelin morphology were comparable between Chd7cKO and control mice ( Supplementary  Fig. 3c,d) , we assessed the function of Chd7 in the remyelination process following lysolecithin-induced demyelination. Local injection of lysolecithin in the white matter induces rapid myelin breakdown followed by myelin regeneration through an OPC recruitment phase at 7 d post-lesion (Dpl 7) and a remyelinating phase at Dpl 14 (ref. 24 ). In normal adult spinal white matter, expression of Chd7 was hardly detectable; however, Chd7 was re-expressed following demyelination induced by lysolecithin beginning at Dpl 7 (Fig. 4a) , and the number of Chd7 + cells increased substantially at Dpl 14 in the lesion (Fig. 4b) .
Chd7 was mainly expressed in Sox10 + OLs and was predominantly confined to CC1 + differentiating OLs at Dpl 14 ( Fig. 4c) .
To determine the potential role of Chd7 in OL regeneration, we examined the re-appearance of myelin genes and OLs in the lesion during remyelination in control and Chd7cKO mice. At Dpl 7 and Dpl 14, Mbp and Plp1 expression and the number of Plp1 + differentiating OLs (Fig. 4d,e ) were substantially reduced in Chd7cKO compared with control lesions. In addition, the number of OL lineage cells, including CC1 + OLs or Sox10 + or Olig2 + cells, in Chd7cKO mice during remyelination was markedly reduced (Fig. 4g,h and Supplementary Fig. 5 ). In contrast, loss of Chd7 did not appear to impair the recruitment of PDGFRα + OPCs ( Fig. 4d ) and the number of OPCs in the lesion was comparable between control and Chd7cKO mice ( Fig. 4d,f) . Notably, far fewer myelinated axons were detected in the lesions of Chd7cKO mice than in controls ( Fig. 4i) . The percentage of myelinating axons and the thickness of newly generated myelin sheaths around axons assessed by g-ratios at Dpl 14 were substantially reduced in Chd7cKO mutants ( Fig. 4j,k) . Similar results of reduction in OL regeneration were obtained for remyelination in the adult corpus callosum of Chd7cKO mice (Supplementary Fig. 6 ). Altogether, these observations indicate that Chd7 has a crucial role in OL remyelination in the context of white matter injury.
Chd7 regulates transcriptional programs for OL maturation
To investigate the underlying molecular mechanisms of dysmyelination in Chd7-deficient animals, we performed transcriptome profiling and analyzed global gene expression patterns in Chd7cKO and control spinal cords at P8. We identified genes altered in Chd7cKO pups that were either upregulated (n = 256) or downregulated (n = 545) relative to controls (fold change ≥ 1.5, P < 0.05; Fig. 5a ). Among those, a cohort of myelin structural genes and critical myelination regulators, including Myrf/Gm98 and Sox10 (refs. 25, 26) , were downregulated in the Chd7cKO spinal cord ( Fig. 5b) npg a r t I C l e S analysis confirmed a marked reduction in myelination-promoting genes, such as Myrf and Sox10, and an increase in differentiation inhibitors, including Id2/4 and Hes1 (Fig. 5c ). Gene ontology (GO) analysis further revealed that the genes downregulated in Chd7-deficient mice are enriched for those that function in cytoskeletal organization and lipid metabolism in addition to myelination ( Fig. 5d ). 27 . Consistently, analysis of the potential gene regulatory network revealed dysregulation in the genes involved in actin assembly and lipid homeostasis, and in OL lineage-enriched genes in Chd7 mutants ( Fig. 5e) . Those alterations were further confirmed by qRT-PCR analysis of Chd7cKO spinal cords ( Fig. 5f,g) . Together, these data suggest that Chd7 manages a gene regulatory network that controls OL differentiation and myelination.
MBP
Chd7 selectively targets enhancers of myeliogenic genes RNA-seq analysis does not establish whether a given regulated transcript is a direct Chd7 target. To identify Chd7 direct target genes, we used chromatin-immunoprecipitation and sequencing (ChIP-Seq) to assess Chd7 genome-wide occupancy in maturing OLs (mOL), which were differentiated from OPCs after 3 d of triiodothyronine (T3) exposure. Chd7 peak density was enriched within ±5-kb elements proximal to transcriptional start sites ( Fig. 6a,b ). Chd7-occupied regions exhibited features of the active chromatin status, characterized by a bimodal distribution of H3K27Ac around Chd7 peaks and co-occupancy of Olig2 (Fig. 6a,c,d) , an OL transcription factor that has been shown to target functional enhancers 22 . Previous studies indicated that Brg1 targets OL-specific enhancers during the initiation of OPC differentiation; however, we note that the majority (~76%) of Chd7 binding regions were not targeted by Brg1 in mOLs ( Supplementary  Fig. 7) , indicating that Chd7 harbors unique molecular functions that control OL maturation. Notably, among Chd7 target genes that were differentially expressed following Chd7 deletion, the majority (~84%) was downregulated ( Fig. 6e,f ), suggesting that Chd7 predominantly functions as a transcriptional activator for promoting the OL differentiation program. Gene ontology analyses revealed a strong association between Chd7targeted loci with several regulatory arms of pathways and modules related to OL maturation ( Fig. 6g ). Among Chd7-targeted genes were those encoding molecules involved in transcriptional control of myelinogenesis (Sox10, Myrf, Olig1, Zfp191 and Sip1/Zeb2), lipid metabolism and cytoskeleton assembly, as well as key myelin components (Mbp, Ugt8, Plp1 and Cnp; Fig. 6h and Supplementary Fig. 8a,b) . When comparing Chd7 binding with those in embryonic stem cells (ESCs) 10 or neural stem cells (NSCs) 8 , the binding sites of Chd7 in OLs minimally overlapped with those in ESCs or in NSCs (Supplementary Fig. 8c ), suggesting a unique role of Chd7 in OL differentiation. Accordingly, Chd7 target genes were generally expressed at relatively high levels in the OL lineage compared with other cell types ( Supplementary Fig. 8d ). The significant correlation between Chd7 occupancy and elevated myelination-associated gene expression further suggests that Chd7 selectively activates specific gene sets for OL differentiation.
To investigate whether any specific DNA sequence motifs were enriched at Chd7 binding sites, we used the de novo DNA motifdiscovery program MEME 28 to identify consensus-sequence motifs associated with Chd7 targeted sites. This analysis revealed that Chd7 binding sites with the consensus binding motif C(T/A)TTG(T/A)(T/A) for Sox10 (MEME motif score E = 5.7 × 10 −97 ; Fig. 6i ), a transcription factor required for terminal differentiation of the OL lineage 29 , were most overrepresented ( Supplementary Fig. 9a ). Dpl To determine whether Chd7 and Sox10 colocalization result from a direct interaction between these two proteins or unrelated occupancy, we performed co-immunoprecipitation by expressing Sox10 and Chd7 in 293T cells or by pulling-down endogenous Sox10 using a Chd7 antibody in an oligodendroglial cell line, Oli-neu, under differentiating conditions 30 . We found that Chd7 formed a complex with Sox10 in the 293T cells transfected with Sox10 and Chd7 and differentiating Oli-neu cells (Fig. 6j,k) , suggesting that Chd7 and Sox10 targeting to these sites occurred through a physical complex of these proteins. To determine whether Sox10 and Chd7 co-occupied the same regulatory elements in mOLs, we then charted genome-wide occupancy of Sox10 in mOL using ChIP-seq. We found that approximately 40% of Chd7 peaks overlapped with those of Sox10 in mOL ( Fig. 6l and Supplementary Fig. 9b,c) , which match with Sox10 peaks in developing spinal cord 29 . Sox10 and Chd7 targeted a common set of OL regulatory genes, including myelination-promoting genes Myrf, Nkx2.2, Sip1, Olig1 and Mbp (Supplementary Fig. 10 ).
Chd7 and Sox10 co-occupied sites were highly enriched with the activating histone mark H3K27ac as compared with the Sox10 loci without Chd7 colocalization (Fig. 6m) . Notably, Sox10 binding exhibited a preference for Chd7-occupied sites (Fig. 6n) . This observation indicates that Chd7 occupancy defines enhancer elements, favoring Sox10 recruitment and a more accessible chromatin state associated with gene activation. Consistently, a combination of Chd7 and Sox10 overexpression enhances the activity of Cnp and Plp1 promoter reporters ( Fig. 6o) and promotes expression of OL differentiation genes to a greater degree than when they were expressed individually in Oli-neu cells (Fig. 6p) . Reduction of both Chd7 and Sox10 by siRNA-mediated knockdown caused much stronger inhibition in the expression of myelination-related genes than individual Chd7 or Sox10 downregulation during OPC differentiation (Fig. 6q) , raising the possibility of genetic interaction and cooperativity between Chd7 and Sox10 in the control of OL differentiation. Notably, Sox10mediated activation of myelin-associated genes was inhibited by the presence of an ATPase-defective mutant variant of Chd7 (Chd7 K998R ) ( Fig. 6r) 9 , suggesting an inhibitory effect of the Chd7 K998R mutant on Sox10 function. Together, these findings suggest that Chd7 and Sox10 have cooperative functions in activating the transcriptional program for OL differentiation.
Osterix and Creb3l2 are Chd7 targets for OL maturation The observation that Chd7 transcriptionally activates an OL-specific gene network prompted us to search for Chd7-driven candidate genes that contribute to OL differentiation. By integrating Chd7 genome occupancy and transcriptome profiling, and considering genes downregulated in the Chd7cKO and occupied by Chd7 as candidate targets, we identified a cohort of potential transcriptional regulators that have yet to be characterized in OL development, including Osterix (Sp7), Creb3l2, Zfp365, Zfp167 and Sorbs3. Notably, Osterix encodes a zinc finger-containing transcription factor that is essential for osteoblast differentiation and bone formation 31 , and Creb3l2 encodes cAMP-responsive element binding protein 3-like 2, a basic leucine zipper (bZIP) transcription factor, which is critical for chondrogenesis 32 a r t I C l e S and Creb3l2 for further characterization because malformations of the temporal bone are also a common feature in CHARGE syndrome 33, 34 . Chd7 targets the proximal elements of both gene loci around transcription start sites marked by H3K4me3 as well as distal enhancer elements marked by H3K27Ac (Fig. 7a) . Expression of Osterix and Creb3l2 was essentially diminished in the spinal cord of Chd7cKO animals (Fig. 7b) while Chd7 overexpression induced Osterix and Creb3l2 expression in OPCs under both proliferation-and differentiation-promoting conditions (Fig. 7c) . Collectively, these data suggest that Chd7 directly activates Osterix and Creb3l2 in the OL lineage.
Consistent with the Chd7 expression pattern, Osterix and Creb3l2 expression levels increased substantially as OPCs differentiated into mature OLs (Fig. 7d) . Similarly, we detected intense Osterix and Creb3l2 protein expression in cultured differentiating OLs bearing complex myelin processes (Fig. 7e,f) . To evaluate the role of these OL-enriched genes in OL differentiation, we knocked down endogenous Osterix and Creb3l2 expression in OPCs using RNA interference (Fig. 7g) . Downregulation of Osterix and Creb3l2 inhibited expression of myelination genes including Cnp, Mbp, Plp1, Mag and Myrf (Fig. 7h) .
Notably, exogenous overexpression of Osterix, but not Creb3l2, restored, at least partially, the defects in expression of myelinationassociated genes caused by Chd7 knockdown in OPCs (Fig. 7i,j) , pointing to the possibility that Osterix may mediate Chd7 function in OL differentiation.
Osterix is uniquely expressed in the OL lineage in the CNS, particularly in newly formed OL, according to neural cell-type transcrip-tome database (Fig. 7k) 35 . To further determine the role of Osterix in OL development in vivo, we examined the expression of markers for mature OLs and OPCs in Osterix-null animals, which die at birth. At embryonic day 18.5 (E18.5), the last collectable stage for Osterix-null embryos, expression of Mbp and Plp1 was markedly diminished in the spinal cord, whereas the number of PDGFRα-expressing OPCs was comparable to that of control littermates (Fig. 7l) . Consistently, expression of MAG and MBP assayed by immunostaining was markedly reduced as compared with the control (Fig. 7m) . These observations indicate that the Chd7 downstream regulator Osterix, an OL-enriched transcriptional regulator, is required for the onset of OL differentiation.
DISCUSSION
The mechanisms underlying neurological deficiency, particularly the white matter defects, in CHARGE syndrome are poorly defined. Chd7 function in OL development has not been explored in any tissues or animal models. We found that Chd7 was highly enriched in differentiating and maturing OLs in the CNS. By generating mice with Chd7 mutated in the OL lineage, we found, to the best of our knowledge for the first time, that Chd7 is required for proper onset of OL differentiation and myelination, as well as remyelination after demyelinating injury. Using a combination of RNA-seq and stage-specific ChIP-seq analyses, we determined an unbiased wholegenome occupancy map for Chd7 direct transcriptional targets for myelinogenesis and revealed Sox10 as a co-regulator of Chd7. comparisons with t test, P Chd7 versus pCIG = 0.008, t Chd7 versus pCIG = 6.397, P Chd7+Sox10 versus Sox10 = 0.0002, t Chd7+Sox10 versus Sox10 = 9.876; Plp1, ANOVA F = 137.6; multiple comparisons with t test, P Chd7 versus pCIG = 0.017, t Chd7 versus pCIG = 4.792, P Chd7+Sox10 versus Sox10 = 0.01, t Chd7+Sox10 versus Sox10 = 5.836; Cnp, ANOVA F = 119.6; multiple comparisons with t test, P Chd7 versus pCIG = 0.013, t Chd7 versus pCIG = 5.344, P Chd7+Sox10 versus Sox10 = 0.01, t Chd7+Sox10 versus Sox10 = 5.794; Myrf, ANOVA F = 57.61; multiple comparisons with t test, P Chd7 versus pCIG = 0.028, t Chd7 versus pCIG = 4.042, P Chd7+Sox10 versus Sox10 = 0.02, t Chd7+Sox10 versus Sox10 = 5.43). (q) Left, qPCR validation of knockdown efficiency of Sox10 and Chd7 in primary rat OPCs under differentiation conditions. The data are presented as mean ± s.e.m. n = 5 biological replicates; Sox10, P = 0.0003, t = 6.017; Chd7, P = 0.016, t = 3.041; two-tailed unpaired Student's t test). Right, qRT-PCR analyses of OL-differentiation associated genes following treatments with scrambled (n = 3), Sox10 (n = 5), Chd7 (n = 5), and both Sox10 and Chd7 siRNAs (n = 5), respectively. Data are presented as mean ± s.e.m. (n, numbers of biological replicates; Mbp, ANOVA F (3, 14) = 36.26; multiple comparisons with t test, P Chd7 versus scrambled = 0.03, t Chd7 versus scrambled = 2.82, P Sox10 versus scrambled = 0.0004, t Sox10 versus scrambled = 6.84, P Sox10+Chd7 versus Sox10 = 0.006, t Sox10+Chd7 versus Sox10 = 3.7; Plp1, ANOVA F (3, 14) = 38.12; multiple comparisons with t test, P Chd7 versus scrambled = 0.015, t Chd7 versus scrambled = 3.34, P Sox10 versus scrambled = 0.0005, t Sox10 versus scrambled = 6.68, P Sox10+Chd7 versus Sox10 = 0.004, t Sox10+Chd7 versus Sox10 = 3.86; Cnp, ANOVA F (3, 14) = 37.99; multiple comparisons with t test, P Chd7 versus scrambled = 0.033, t Chd7 versus scrambled = 2.74, P Sox10 versus scrambled = 0.0002, t Sox10 versus scrambled = 7.55, P Sox10+Chd7 versus Sox10 = 0.01, t Sox10+Chd7 versus Sox10 = 3.15; Myrf, ANOVA F (3, 14) = 21.45; multiple comparisons with t test, P Sox10 versus scrambled = 0.002, t Sox10 versus scrambled = 5.74, P Sox10+Chd7 versus Sox10 = 0.03, t Sox10+Chd7 versus Sox10 = 2.69). (r) qRT-PCR analyses of differentiated OL markers Mbp, Cnp and Myrf in Oli-Neu cells transduced with Sox10, Chd7 K998R mutant form or both under proliferation condition. The data are presented as mean ± s.e.m. (n = 4 independent experiments; Mbp, ANOVA F (3, 12) = 8.803; multiple comparisons with t test, P Sox10 versus pCIG = 0.022, t Sox10 versus pCIG = 3.062, P Sox10+Chd7 K998R versus Sox10 = 0.025, t Sox10+Chd7 K998R versus Sox10 = 2.97; Cnp, ANOVA F (3, 12) = 4.802; multiple comparisons with t test, P Sox10 versus pCIG = 0.035, t Sox10 versus pCIG = 2.706, P Sox10+Chd7 K998R versus Sox10 = 0.035, t Sox10+Chd7 K998R versus Sox10 = 2.71; Myrf, ANOVA F (3, 12) = 12.76; multiple comparisons with t test, P Chd7 K998R versus pCIG = 0.031, t Chd7 K998R versus pCIG = 2.79, P Sox10 versus pCIG = 0.014, t Sox10 versus pCIG = 3.447, P Sox10+Chd7 K998R versus Sox10 = 0.015, t Sox10+Chd7 K998R versus Sox10 = 3.41). *P < 0.05, **P < 0.01 and ***P < 0.001. npg a r t I C l e S We further identified new Chd7 targets such as an osteoblastdifferentiation factor, Osterix, as a critical OL differentiation regulator. Thus, our results identify hitherto previously uncharacterized Chd7 functions in white matter pathogenesis and reveal that Chd7 acts as a molecular nexus of the critical regulatory networks that contribute to defects in distinct cells lineages affected in CHARGE syndrome.
Chd7 controls the onset of myelination and remyelination Epigenetics and chromatin remodeling are increasingly appreciated to be critical for development and human diseases. We found that loss of function in Chd7 leads to defects in CNS myelination and remyelination. The dysmyelinating phenotype in our mouse model resembled some of the features observed in CHARGE syndrome with proven CHD7 mutations, including delayed myelination and white matter defects (Fig. 1m,n) 13, 14 .
Our data suggest that Chd7 regulates OPC differentiation in a cell-autonomous manner. Deletion of Chd7 did not appear to affect the developmental transition from Olig + progenitors to PDGFRα + OPCs, but instead blocked proper transitioning from OPC to OL. Consistently, temporal-specific Chd7 deletion in PDGFRα + OPCs led to a failure of OPCs to differentiate. In addition, our studies using a LPC-induced demyelinating animal model further revealed that Chd7 is critical for remyelination and is therefore an important determinant of effective myelin repair.
The genome-wide, base-resolution mapping of the Chd7-targeted cistrome revealed that Chd7 selectively targets the enhancers of myelinogenic factors, including Myrf, Nkx2.2, Sip1 and Olig1, and activates a transcriptional program for OL differentiation, consistent with the Chd7 function as a transcriptional rheostat to regulate or fine-tune gene expression levels 10 . Notably, we found that the majority of targeting sites by Chd7 are distinct from those by Brg1, another ATP-dependent (Supplementary Fig. 7 ), suggesting that distinct ATP-dependent chromatin remodeling factors such as Chd7 and Brg1 exert unique functions to regulate the OL maturation process. We further identified a cohort of previously uncharacterized Chd7 targets in OL such as the bone formation regulators Osterix and Creb3l2, and found that these transcriptional factors were also critical for oligodendroglial maturation. Despite its role in osteoblast lineage differentiation 31 , Osterix is expressed predominantly in maturing OLs in the CNS. We found that Osterix positively regulated OL differentiation in vitro and in vivo. It is worth noting that Osterix regulates expression of osteopontin, which is associated with multiple sclerosis pathogenesis 36, 37 . Given that malformations of the temporal bone are a common feature in CHARGE syndrome 33, 34 , it is possible that regulation of Osterix by Chd7 may also contribute to temporal bone defects in CHARGE patients. These observations suggest that Chd7-controlled gene regulatory networks for OL differentiation may serve as an important intracellular cue for controlling the myelination process in the CNS and other seemingly unrelated malformations of other organs in CHARGE patients.
Chd7 interacts with Sox10 to regulate myelinogenic program
As an ATP-dependent nucleosome-remodeling factor, Chd7 requires additional transcriptional cofactors to target and activate gene expression. Our results identify Sox10 as an important co-activator of Chd7 for target gene transcription during OL differentiation. Notably, mutations in Sox10 and Chd7 are both reported in Kallmann syndrome, a congenital disorder that exhibits hypogonadotropic hypogonadism and anosmia, features that are also frequently present in CHARGE syndrome 38 . The clinical relevance between Sox10 and Chd7 mutations in these human diseases indicate a potential convergent role in developmental and pathogenic processes. Although the interaction of Chd7 with Sox10 provided the mechanistic basis for the role of Chd7 in myelinogenesis, the Chd7 mutant phenotype in mice seems less severe than that caused by deletion of Sox10 (ref. 25) . These data suggest that Chd7 is an important accessory factor that quantitatively enhances the OL differentiation and myelination program that can proceed in its absence, but at a lower level. Another possible explanation could be redundancy with other CHD family proteins, such as CHD8, which is also highly expressed in oligodendrocytes (data not shown) and has been implicated in CHARGE syndrome pathogenesis through binding with Chd7 (ref. 39) .
How Chd7 is temporally and spatially targeted to specific sites in chromatin remains to be determined. Recruitment of pioneer transcription factors by DNA consensus motifs clustered on regulatory elements could prime chromatin, which in turn recruits remodeling factors for activating downstream target gene expression 40, 41 . Consistent with this, Olig2 has been shown to act as a prepatterning factor that directs the recruitment of Brg1 to OL lineage-specific regulatory elements during the transition from OPC to immature OL 22 . Our analysis of the Chd7 and Sox10 binding cistrome revealed that Sox10 preferentially occupies Chd7-targeted elements, whereas the frequency of Chd7 occupancy was comparable between elements with or without Sox10 targeting (Supplementary Fig. 11a) . Given that Sox10 occupancy in genomic loci increases gradually over the course of OPC maturation 42 , it seems likely that Chd7 is targeted to the chromatin first and then recruits Sox10. Notably, Olig2 and Chd7 genome-wide binding cistromes indicate that Olig2 might be a prerequisite for the recruitment of Chd7 to regulatory elements (Supplementary Fig. 11b ). Thus, a potential sequential recruitment of priming factors such as Olig2 and chromatin remodeling machin-ery such as Brg1 and Chd7, followed by late-phase regulators such as Sox10, may occur during OL lineage progression.
Implications for human diseases
We found dysmorphic white matter in a significant portion of CHARGE patients with proven CHD7 mutations. The critical role that we observed for Chd7 in CNS myelination through OL lineage-specific mutagenesis implies that mutations in CHD7 may contribute to myelination and white matter defects seen in patients with CHARGE syndrome. A substantial proportion of CHARGE patients develop growth retardation or delay, ranging from mild to severe. Given that white matter abnormalities caused by CHD7 mutations appear to be more severe in some CHARGE patients compared with those in Chd7cKO mice, it is possible that altered expression or activity of Chd7 in other neural cell types, such as neurons or neural stem cells 43 , may also contribute to the human phenotype. Nonetheless, we found that Chd7 was highly enriched in differentiating OLs and was critical for CNS myelination and remyelination. These observations suggest that dysmyelination caused by CHD7 mutations might contribute, at least partially, to developmental white matter defects seen in CHARGE patients 14 . Although heterozygous Chd7 knockout mutants in the OL lineage were phenotypically normal, depletion of Chd7 expression in mice caused a myelination deficiency, indicating that a minimum threshold level of Chd7 expression is necessary for myelinogenesis. The phenotypic variation between the CHD7 haploinsufficient humans 5 and heterozygous knockout mice could be a result of a differential sensitivity to gene dosage across species or dominant-negative effects of human mutant proteins.
Our results also provide multiple lines of functional genomics data that shed light on the molecular basis by which Chd7 directly regulates not only a network of genes essential for OL myelination, but also genes associated with development and morphogenesis of multiple organs, including craniofacial, eye and ear structures, that are affected in CHARGE patients 5 . Examples include genes involved in the developmental processes of craniofacial and bone development such as Osterix, Creb3l2, Col2a, Fgfr1/2 and Rarg 31,44 , eye development such as Pax6, Mitf and Rarg 45, 46 , and ear development such as Ddr1, Prkra, Foxg1, Fgfr1/2 and Rarg [47] [48] [49] (Supplementary Fig. 12) . Notably, retinoic acid receptor gamma (Rarg) acts as a direct target of Chd7 in OLs (Supplementary Fig. 12) , consistent with recent reports that Chd7 regulates the expression of Rarg 43 . Given that Rarg signaling serves as a positive regulator of OL myelination and remyelination 50 , its downregulation in Chd7 mutants may also contribute to CNS myelination defects in CHARGE syndrome. Together, our findings indicate that Chd7 serves as a nodal point of the regulatory network for the development of a diverse array of lineages spanning OLs and other cell types including osteoblasts, encompassing the phenotypes in CHARGE patients. Our unbiased genome-wide target gene analysis could provide a molecular framework for identifying signaling pathways and molecules as therapeutic targets for promoting myelin regeneration in patients with demyelinating diseases and CHARGE syndrome.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. RNA-seq and ChIP-seq data have been deposited in the NCBI Gene Expression Omnibus under accession code GSE72727. npg a r t I C l e S Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS

Animals and subjects.
Mice homozygous for floxed alleles of Chd7 (Chd7 loxP/loxP ) 51 were crossed with mice carrying Cre recombinase driven by the Olig1 promoter (Olig1-Cre +/− ) 52 to generate Chd7cKO (Chd7 loxP/loxP ;Olig1-Cre +/− ) and heterozygous control (Chd7 loxP/+ ;Olig1-Cre +/− ) mice. Generation of Brg1cKO mice has been described previously 22 . Briefly, Brg1 loxP/loxP mice 53 were crossed with Olig1-Cre mice to generate Brg1cKO (Brg1 loxP/loxP ;Olig1-Cre +/− ) and heterozygous control (Brg1 loxP/+ ;Olig1-Cre +/− ) mice. Osterix (Sp7) mutant mice have been described previously 31 , in which an IRES-lacZ-polyA/loxP-flanked PGK neo-bpA cassette is inserted into the second coding exon of Osterix. PDGFRα-CreER T BAC mice 23 and Rosa26 tdTomato reporter mice (Ai14, Jackson Laboratory) were crossed with Chd7 loxP/loxP mice to generate the OPC-specific iKO mice. Animals of either sex were used in the study and littermates were used as controls unless otherwise indicated. The mouse strains used in this study were generated and maintained on a mixed C57Bl/6;129Sv background and housed (three or less animals per cage) in a vivarium with a 12-h light/dark cycle. All animal studies were approved by the Institutional Animal Care and Use Committees of the Cincinnati Children's Hospital Medical Center, USA, and Sorbonne Universités, UPMC University Paris 06, France. MRI images of CHARGE patients including males and females from age 2 to 15 were evaluated by neuroradiologists and compared with age-matched controls. All human patient images were obtained with informed consent as outlined by the institutional review board at the Cincinnati Children's Hospital Medical Center. tissue processing and in situ hybridization. Mice at various developmental stages were anesthetized with ketamine/xylazine and perfused with phosphatebuffered saline (PBS) followed by 4% paraformaldehyde (PFA). Spinal cords or brains were dissected, fixed in 4% PFA overnight, dehydrated in 20% sucrose at 4 °C, embedded in OCT and cryosectioned at 16 µm. For tamoxifen treatment of PDGFRα-CreER T -Chd7 loxP/loxP mice, tamoxifen (T5648) was dissolved in corn oil (Sigma, C-8267) and injected intraperitoneally at 3 mg per 40 g of body weight per day. In situ hybridization was performed as previously described 54 . Digoxigenin-labeled riboprobes used in the study were: murine Mbp, Plp/Dm-20 and Pdgfra. electron microscopy. Tissue processing was performed essentially as described previously 22 . Briefly, mice were deeply anesthetized with ketamine/xylazine, perfused with 0.1 M cacodylate, followed by 2.5% paraformaldehyde/2.5% glutaraldehyde in 0.1 M cacodylate (pH 7.2). Spinal cord and optic nerves were dissected and postfixed in 1% OsO 4 . Ultrathin sections were stained with lead citrate for electron microscopy imaging.
Immunohistochemistry and immunoblotting. Cryosections (12-µm thick) or vibratome sections (50-µm thick) were permeabilized and blocked in blocking buffer (0.3% Triton X-100 and 5% normal donkey serum in PBS) for 1 h at 25 °C and overlaid with primary antibodies overnight at 4 °C. Antibodies used in the study were: rabbit anti-Olig2 (Millipore, AB9610, 1:5000), rat anti-PDGFRα (BD Bioscience, 558774, 1:600), mouse anti-APC (CC1, Oncogene Research, OP80, 1:150), goat anti-MBP (Santa Cruz Biotechnology, sc-13914, 1:400), mouse anti-MOG (8-18C5, DSHB, 1:500), rabbit anti-Chd7 (Cell signaling, 6505, 1:300), rabbit anti-Chd7 (Abcam, AB38124, 1:600), goat anti-Osterix/Sp7 (Santa Cruz Biotechnology, sc-22538, 1:300), rabbit anti-Creb3l2 (Santa Cruz Biotechnology, sc-366044, 1:300). After washing with 0.4% Triton X-100 in PBS, cells or sections were incubated with secondary antibodies conjugated to Cy2, Cy3 or Cy5 (Jackson ImmunoResearch Laboratories, 1:1,000) for 2 h at 25°C, stained in DAPI for 5 min, washed in PBS and mounted with Fluoromount-G (SouthernBiotech). Cell images were quantified in a double-blinded manner. For immunoblotting, whole cell lysates were prepared 48 h after transfection by using 1 × Passive Lysis Buffer (Promega) supplemented with a protease inhibitor cocktail (1:200, Sigma). After western blotting, proteins were detected with appreciate secondary antibodies by using chemiluminescence with the ECL kit (Pierce) according to the instructions of the manufacturer.
Stereological estimation of white matter volume. White matter area was determined by measuring the MBP immunoreactive region as previously described 55 . The volumetric analysis of MBP-positive tissue was performed according to the method described previously 56 using the following formula: V = SA· p · T, where V is the total volume, SA is the sum of the area measured, p is the inverse of the section sampling fraction, and T is the section thickness. ol culture and transduction. Primary rat OPCs were isolated as described 57 with slight modifications. Briefly, mixed glial cells were initially cultured in DMEM-F12 medium supplied with 15% FBS, then switched to B104 conditioned medium for 2 d before isolating OPCs by mechanical detachment in an orbital shaker. Isolated rat OPCs were grown in Sato growth medium supplemented with mitogens 10 ng ml −1 PDGF-AA and 20 ng ml −1 bFGF, and differentiated in OL Differentiation Medium (Sato medium supplemented with 15 nM T3 and 10 ng/ml ciliary neurotrophic factor). Mouse OPCs were isolated from P5-6 cortices by immunopanning with antibodies against Ran-2, GalC and O4 sequentially as previously described 58 . OPCs were transduced with adenoviral vectors carrying GFP control or Cre-GFP and analyzed by immunofluorescence.
lysolecithin-induced demyelinating injury. Lysolecithin-induced demyelination was carried out in the ventrolateral spinal white matter of approximately 8-week-old mice. Anesthesia was induced and maintained by peritoneal injection of a mixture of ketamine (90 mg per kg) and xylazine (10 mg per kg). After exposing the spinal vertebrae at the level of T9-T12, meningeal tissue in the intervertebral space was cleared, and the dura was pierced with a dental needle. 0.5 µl of 1% lysolecithin (L-a-lysophosphatidylcholine, Sigma L4129) via a Hamilton syringe attached a glass micropipette was injected into the ventrolateral white matter via a stereotactic apparatus. Spinal cord tissues carrying the lesions were collected at different time points. For demyelination in the brain, focal demyelinating lesions were induced by stereotaxic injection of 1.5 µl lysolecithin solution (1% in 0.9% NaCl) into the corpus callosum at coordinates: 1 mm lateral, 1.3 mm rostral to bregma, 1.7 mm deep to brain surface) using a glass-capillary connected to a 10 µl Hamilton syringe. Animals were left to recover in a warm chamber before being returned into their housing cages. LPC-induced injuries were conducted in a genotype-blinded manner.
RnA extraction and qRt-PcR. Analyses were conducted with RNA extracts from spinal cord tissue of mutant mice and their littermate controls. Total RNA was extracted per the Trizol (Life Technologies) protocol. cDNA was generated with iScript cDNA Synthesis Kit (Bio-Rad). qRT-PCR was performed using the ABI Prism 7700 Sequence Detector System (Perkin-Elmer Applied Biosystems). qRT-PCR primers for mouse gene sequences were: Plp-f, TGCTCGGCTGTAC CTGTGTACATT, Plp-r, TACATTCTGGCATCAGCGCAGAGA; mouse Mbp-f, TCACAGAAGAGACCCTCACA; Mbp-r, GCCGTAGTGGGTAGTTCTTG; Cnp1-f, TCCACGAGTGCAAGACGCTATTCA, Cnp1-r, TGTAAGCATCAGCG GACACCATCT; Chd7-f, GCCTCTCATCACGTACAGCA, Chd7-r, GGATGGG GGATTTGTCCTAC; Elovl1-f, GAAAGGGCTGGACACTTACTT, Elovl1-r, CCTCTTCAGTGTGAGGAGAAAG; Creb3l2-f, AAGAATACATGGACAGC CTGG; Creb3l2-r, TTCCCCATCACCAAAGTCTG; Sorbs3-f, AGATACAC TGGACTCCGTACC; Sorbs3-r, CAAATTTCTGAGTTCGCCGG; Creb3l2-f, CATCACCAGCACCTCTCATC; Creb3l2-r, CCATTTCTCACTCTCCACCTC; Gapdh-f, TGCCAAATATGATGACATCAAGAA, Gapdh-r, GGAGTGGG TGTCGCTGTTG.
chIP-Seq and data analysis. Rabbit anti-Chd7 (Cell signaling, 6505) and anti-Sox10 (Abcam, ab155279) antibodies were used for immunoprecipitation experiments. ChIP-seq assays were performed essentially as previously described 22 . Briefly, nuclear suspensions of OLs were sonicated with a Covaris S220 sonicator (total time 8 min). Antibody (chromatin: antibody = 4:1) was added to chromatin and incubated at 4 °C overnight. Chromatin-protein complex was immunoprecipitated with protein A/G plus agarose beads and washed sequentially. The ChIP-seq libraries were prepared using NEBNext ChIP-seq Library Prep Master Mix Set for Illumina (NEB cat E6240L), and then run on the Illumina sequencer HS2000.
FASTQ files of ChIP-seq data were aligned to March 2012 rat genome assembly (RGSC Rnor_5.0/rm5) using Bowtie with the following options: -p 8, -m 1. Resulting SAM files were converted to BAM format using SAM tools. Peak calling was performed using MACS (Model-based Analysis of ChIP-Seq) (http://liulab. dfci.harvard.edu/MACS) with a P value cut off of 10 9 .
